ConductScience.org, home

Paper17526555

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

Syversen SW and 8 others. Ann Rheum Dis, 2008. Cited by 243 papers, by iCite.

Cite this record

ConductScience Library. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Papers, record 17526555. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17526555

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
PubMed
Journal
Ann Rheum Dis
PubMed
Year
2008
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
243
iCite
Relative citation ratio, by iCite
6.65
iCite
Revised in PubMed
2025-02-14
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Syversen SWS W
2Gaarder PIP I
3Goll GLG L
4Ødegård SS
5Haavardsholm EAE A
6Mowinckel PP
7van der Heijde DD
8Landewé RR
9Kvien TKT K

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Arthritis, RheumatoidMajor topic
Peptides, CyclicMajor topic
Algorithms
Antirheumatic Agents
Autoantibodies
Biomarkers
Cohort Studies
Disease Progression
Female
Humans
Immunoglobulin A
Immunoglobulin G
Longitudinal Studies
Male
Middle Aged
Odds Ratio
Predictive Value of Tests
Radiography
Rheumatoid Factor
Sex Factors

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03265236Diagnostic Value of Anti-MCV in Pts With RABackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by115

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 243 citations.

PMIDTitleJournalYearIn PapersSource
42836514Temporal Patterns of Outcomes After DMARD Tapering or Withdrawal in Rheumatoid Arthritis With Sustained Disease Control: A Systematic Review and Meta-Analysis.Clin Transl Sci2026https://conductscience.org/library/papers/42836514PubMed
42192467Radiographic outcome over 15 years in patients with early rheumatoid arthritis - a BARFOT-study.BMC Rheumatol2026https://conductscience.org/library/papers/42192467PubMed
42134050Aggressive Seropositive Rheumatoid Arthritis With Diffuse Osteolytic Bone Lesions, Hypercalcemia, and Lymphadenopathy Masquerading as Hematologic Malignancy: A Case Report.J Investig Med High Impact Case Rep2026https://conductscience.org/library/papers/42134050PubMed
41095913Structural and Functional Outcomes in Rheumatoid Arthritis After 10-Year Therapy with Disease-Modifying Antirheumatic Drugs Under Tight Control: Evidence from Real-World Cohort Data.J Clin Med2025https://conductscience.org/library/papers/41095913PubMed
40757796Abnormal Ulnar Variance: A New Perspective in Rheumatoid Arthritis-Related Joint Damage.Arch Rheumatol2025https://conductscience.org/library/papers/40757796PubMed
40670424Polygenic risk scores of rheumatoid arthritis associated with seropositivity and bone erosions in a Taiwanese population.Sci Rep2025https://conductscience.org/library/papers/40670424PubMed
40204305Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study.BMJ Open2025https://conductscience.org/library/papers/40204305PubMed
40091354Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis.Innate Immun2025https://conductscience.org/library/papers/40091354PubMed
38843126Differences in referral path, clinical and radiographic outcomes between seronegative and seropositive rheumatoid arthritis Mexican Mestizo patients: A cohort study.PLoS One2024https://conductscience.org/library/papers/38843126PubMed
37809106Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion.Front Immunol2023https://conductscience.org/library/papers/37809106PubMed
37475973Clinical Implications of Shared Epitope and Anti-citrullinated Peptide Antibody in Patients With Rheumatoid Arthritis.J Rheum Dis2022https://conductscience.org/library/papers/37475973PubMed
37362488Association of the Clinical and Radiographic Findings at Onset With Future Joint Destruction in Patients With Rheumatoid Arthritis.Cureus2023https://conductscience.org/library/papers/37362488PubMed
36581910Erosion-free rheumatoid arthritis: clinical and conceptional implications-a BARFOT study.BMC Rheumatol2022https://conductscience.org/library/papers/36581910PubMed
36425102Inflammatory profile of incident cases of late-onset compared with young-onset rheumatoid arthritis: A nested cohort study.Front Med (Lausanne)2022https://conductscience.org/library/papers/36425102PubMed
36165675Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.Rheumatology (Oxford)2023https://conductscience.org/library/papers/36165675PubMed
35885675Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic Drugs.Diagnostics (Basel)2022https://conductscience.org/library/papers/35885675PubMed
35270012Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments.Int J Mol Sci2022https://conductscience.org/library/papers/35270012PubMed
34980246Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.Arthritis Res Ther2022https://conductscience.org/library/papers/34980246PubMed
34964030A not-to-miss Cause of Severe Cervical Spine Pain in a Patient with Rheumatoid Arthritis: A Case-Based Review.Mediterr J Rheumatol2021https://conductscience.org/library/papers/34964030PubMed
34671034Augmenting MNK1/2 activation by c-FMS proteolysis promotes osteoclastogenesis and arthritic bone erosion.Bone Res2021https://conductscience.org/library/papers/34671034PubMed

See all 115 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17526555

GET https://conductscience.org/api/papers/v1/17526555/cited_by?page=2